^
Association details:
| Biomarker: | CHD8 mutation |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab
Excerpt:
The mutations of CHD8 was significantly higher in patients with PFS ≥ 12 month….CHD8 mutation frequencies was significantly different between the two groups (Fig. 2), detected only in the PFS ≥ 12 months group (Fisher p = 0.0287).
DOI:
10.1016/j.ebiom.2020.102731